Navigation Links
Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
Date:6/4/2009

that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; and Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer. Thiarabine is a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for ProLindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and initiate clinical trials, the value of its products in the market (including MuGard and the size of the overall market for mucositis products), its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.<
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results
2. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
3. First U.S. Patients Enrolled in the REALISM Continued Access Study
4. Access Pharmaceuticals Presents new Combination Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
5. Wrist Access Safer, Easier for Many Patients Undergoing Minimally Invasive Treatment of Blocked Heart Arteries
6. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
7. Unprecedented 8th Year Start Up of National Direct AmeriCorps Program Access to Care Through Service (ACTS) Parent, Lead Organization The Philadelphia AIDS Consortium and World Health Care Infrastructures
8. St. Jude Study Gives New Insights Into How Cells Accessorize Their Proteins
9. McGraw-Hill Professional Launches Drug Effectiveness Resource on AccessPharmacy
10. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
11. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) ... announced registered offering of common shares in ... the Offering, the Company issued 7,286,432 common shares at ... proceeds of approximately $1.45 billion. On March 18, 2015, ... Commission a final prospectus supplement to its effective shelf ...
(Date:3/27/2015)... , March 27, 2015 As ... shipments of incontinence devices for women. ... the most gratifying part is the hundreds of ... women whose lives have been positively impacted by ... of InControl. InControl recently released Apex, ...
(Date:3/27/2015)... 2015   Hospira, Inc. (NYSE: ... the world,s leading provider of injectable drugs and ... evaluation of biosimilarity of its proposed biosimilar, Epoetin ... (FDA) conditionally approved name of RETACRIT™, compared to ... study data were presented at the National Kidney ...
Breaking Medicine Technology:Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3
... Primary Endpoint of the Trial to Be Clarified ... Arbios Systems, Inc.,(OTC Bulletin Board: ABOS) announced today ... U.S. Food and Drug Administration ("FDA") of,an Investigational ... for SEPET(TM), Arbios, extracorporeal (outside the body) artificial,liver ...
... Feb. 21 Accumetrics, Inc. a privately-held,medical device ... tests that,measure patient response to antiplatelet drugs, announced ... Series D financing. The syndicate was led by,Arnerich ... Also participating,in the round were previous investors: Essex ...
Cached Medicine Technology:Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM) 2Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM) 3Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM) 4Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial 2
(Date:3/28/2015)... March 28, 2015 "Necrorun" was featured ... takes a look at the latest and coolest applications ... Troohey, the host of NewsWatch and technology expert, conducted ... is an entertaining endless runner game with knights, nature, ... was released in 2009, according to Eurogamer. The popularity ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 With ... in the fields of osteoporosis, osteoarthritis and musculoskeletal ... Osteoporosis, it may be the first time in ... research forum that the hot-button topic is an ... on the well-accepted scientific principles of Wolff’s law, ...
(Date:3/28/2015)... March 28, 2015 The California-based leading ... for every customer shopping on UniWigs during the Easter ... be a big promotion on April Fools’ Day. , ... is just around the corner. Easter Festival, with religious ... is a major holiday after Christmas. The best wig ...
(Date:3/28/2015)... FL (PRWEB) March 28, 2015 ... conditions coverage is made available to all visitors who ... effective immediately. All members are encouraged to purchase the ... to avoid lack of proper coverage for pre-existing medical ... from one or two medical conditions with serious consequences ...
(Date:3/28/2015)... 28, 2015 Centurion Service Group will be ... Thursday, April 2 at their Las Vegas warehouse, located at ... The sale, which consists of equipment from hospitals and surgery ... 9 a.m. PDT. , Buyers will find items of ... “We are a one-stop-shop,” said Erik Tivin, CEO of Centurion. ...
Breaking Medicine News(10 mins):Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Medical Equipment Auction to Take Place in North Las Vegas 2
... no proof the procedures work and serious side effects ... News) -- Claims by spas that "lipodissolve" injections can ... also remains in question, according to warning letters issued ... The FDA warned six U.S. based medical spas and ...
... iron to Alzheimer,s disease, heart disease, and other age-related disorders, ... suggests specific steps that older consumers can take to ... their bodies. "This story of copper and iron toxicity, which ... is virtually unknown to the general medical community, to say ...
... ... announced today that it has appointed Mick Simon to serve as Executive Vice President ... Business Intelligence Solutions and personal health management clinical services to self insured employers, other ... , ...
... Adherence to treatment declines if adults fail to monitor, ... Children and teens with type 1 diabetes are less ... parents become lax about monitoring their treatment or if ... found. , Failure to properly manage type 1 diabetes, ...
... hooking up takes over from dating as a means of ... to prefer dating whereas more men than women rate hooking ... risks to dating and hooking up. Carolyn Bradshaw from James ... that motivate college men and women to hook up or ...
... this as troubling individually and for society , WEDNESDAY, ... mobility are increasing among middle-age Americans, a new study ... long-term consequences for the U.S. health-care system. , Researchers ... data from the annual National Health Interview Survey, covering ...
Cached Medicine News:Health News:FDA Issues Warning on 'Fat-Melting' Spa Injections 2Health News:HCMS Group LLC Names Mick Simon Chief Operating Officer 2Health News:Kids Need Parents' Help in Managing Type 1 Diabetes 2Health News:Hooking up or dating: Who benefits? 2Health News:Middle-Age Americans Less Mobile Than Ever 2
Silicone Foley Catheters 2-Way (Pediatric)...
Midstream Catch Kits...
Midstream Catch Kits...
... The Pediatric BladderScan® is ... Diagnostic Ultrasound's trusted family ... enabling healthcare providers to ... volume noninvasively, this easy-to-use, ...
Medicine Products: